GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235
GlaxoSmithKline plc (GSK, NYSE: GSK) has completed its acquisition of 35Pharma Inc., a Canadian biopharmaceutical...
Fineline Cube
Shionogi Launches Corporate Venture Capital Initiative with Strategic Investment in Ophthalmology Startup Restore Vision
Shionogi & Co., Ltd. (TYO: 4507) has announced the completion of its first corporate venture...
Zai Lab and Boehringer Ingelheim Partner on DLL3 Combination Therapy for Neuroendocrine Cancers
Zai Lab (NASDAQ: ZLAB, HKG: 9688) and Boehringer Ingelheim (BI) have announced a strategic clinical...
3SBio and Tigermed Forge Strategic Alliance to Create Full-Chain Pharmaceutical Innovation Ecosystem
3SBio Inc. (HKG: 1530) and Hangzhou Tigermed Consulting Co., Ltd. (SHE: 300347, HKG: 3347), China’s...
Daiichi Sankyo to Divest Healthcare Subsidiary to Suntory in $1.6 Billion Strategic Realignment
Daiichi Sankyo Co., Ltd. (TYO: 4568) has announced an agreement to transfer all shares of...
Bayer AG Secures NMPA Approval for Hyrnuo (Sevabertinib) to Treat HER2-Mutant NSCLC in China
Bayer AG (ETR: BAYN) announced that China’s National Medical Products Administration (NMPA) has granted marketing...
Johnson & Johnson Partners with Shanghai Pharmaceuticals for Exclusive Promotion of Paliperidone Palmitate Long-Acting Injection in China
Johnson & Johnson (J&J, NYSE: JNJ) has entered into an exclusive marketing promotion agreement with...
Novo Nordisk Partners with OpenAI to Accelerate Drug Discovery and Transform Healthcare Operations
Novo Nordisk (NYSE: NVO) announced on April 14, 2026, a strategic partnership with OpenAI that...
Fosun Pharma Advances Dual-Target CAR-T Therapy FKC289 into Clinical Trials for Rare Kidney and Blood Disorders
Shanghai Fosun Pharmaceutical Group Co., Ltd. (SHA: 600196, HKG: 2196) announced it has received regulatory...
China’s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives
The State Council released the “Opinions on Improving the Drug Pricing Mechanism” this week, introducing...
Gan & Lee Pharmaceuticals Doses First Patient in Phase III Trial for Novel Long-Acting Insulin GZR33 in Type 2 Diabetes
Gan & Lee Pharmaceuticals (SHA: 603087) announced the first subject dosing in a Phase III...
AC Immune and Eli Lilly Amend 2018 Alzheimer’s Partnership to Advance Tau Morphomer Candidates
AC Immune SA (NASDAQ: ACIU) and Eli Lilly and Company (NYSE: LLY) announced a revised...
Autobio Diagnostics Expands Global IVD Footprint with Dual Vietnam Partnerships
Autobio Diagnostics Co., Ltd. (SHA: 603658) announced this week it has executed separate strategic partnership...
Er-Kim Secures Exclusive CEE Commercial Rights for LOQTORZI Anti-PD-1 Antibody from LEO Pharma
Er-Kim announced on April 14, 2026, that it has signed an exclusive commercialization agreement with...
UCB Secures EU Approval for Kygevvi as First-Ever Treatment for Ultra-Rare TK2 Deficiency
UCB (EBR: UCB) announced that the European Commission (EC) has granted marketing approval under exceptional...
Eli Lilly Restructures China Cardiometabolic Division Ahead of Foundayo Oral GLP-1 Launch
Eli Lilly and Company’s (NYSE: LLY) China unit announced a comprehensive organizational restructuring and key...
Huadong Medicine’s Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication
Huadong Medicine Co., Ltd. (SHE: 000963) announced that the National Medical Products Administration (NMPA) has...
Lepu Medical Acquires Betagrin Rights from Bio-Thera in RMB 450 Million Cardiovascular Deal
Lepu Medical Technology (SHE: 300003), a leading Chinese provider of cardiovascular disease solutions, announced it...
Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate
Eli Lilly and Company (NYSE: LLY) announced plans to acquire CrossBridge Bio, a Houston-based biotechnology...
Laekna Therapeutics Reports Breakthrough Phase III Results for LAE002 AKT Inhibitor in HR+/HER2- Breast Cancer
Laekna Therapeutics Shanghai Co., Ltd. (HKG: 2105) announced positive top-line results from a Phase III...